When was Genoskin founded?

Genoskin was founded in 2011 and raised its 1st funding round 7 years after it was founded.

Where is Genoskin located?

Genoskin is headquartered in Toulouse, France.

How many employees does Genoskin have?

As of Jul 31, 2026, the latest employee count at Genoskin is 64.

Is Genoskin a funded company?

Genoskin is a funded company, having raised a total of $5.4M across 5 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on Jun 01, 2018.

When was the latest funding round of Genoskin?

Genoskin's latest funding was a $***** Series A round on Sep 16, 2025, with participation from 2 investors. Its primary sector is Biopharma Outsourcing. In France, the Biopharma Outsourcing sector has seen $31.7M in funding in 2026 to date.

Where does Genoskin rank among its competitors?

Genoskin ranks 1st amongst 91 active competitors, of which 12 are funded. It stands 2nd in terms of total funding among its competitors. The most recent competitor to raise funding was Syntax Bio, which secured $14.4M in Jun, 2026.

Who are the top competitors of Genoskin?

Genoskin's top competitors include Cayman Chem, PhenoVista and Syntax Bio. Among them, Syntax Bio secured the most recent funding round in June, 2026.

Genoskin - 2026 Company Profile, Funding & Competitors

Genoskin is a series A company based in Toulouse (France), founded in 2011. It operates as an In vitro human skin models for preclinical toxicity and efficacy testing. Genoskin has raised $5.4M in funding from OCCTE. The company has 91 active competitors, including 12 funded and 10 that have exited. Its top competitors include companies like Cayman Chem, PhenoVista and Syntax Bio.

Company Details

Genoskin, founded as a spin-off of from the French National Center for Scientific Research (CNRS) and The Paul Sabatier University in Toulouse is engaged in the development of ex vivo human skin models for preclinical efficacy and toxicity testing of potential drug candidates and might help in reducing the use of lab animals. The company claims to keep real human skin tissue alive for 7 days in human skin models and that they are the closest alternative to in vivo clinical testing. The company claims that its human skin collection process is as per the Declaration of Helsinki. The company has a BSL 2 cell culture rooms and 3D imaging technologies. They have proprietary human skin models such as Oncoskin, which can be used to study melanoma and Hyposkin to study subcutaneous injections.

Website: genoskin.com
Social
Email ID: *****@genoskin.com
Phone Number: +33 **********

Key Metrics

Founded Year

2011

Location

Toulouse, France

Stage

Series A

Total Funding

$5.4M in 5 rounds

Latest Funding Round

Series A, Sep 16, 2025, $*****

Investors

OCCTE & 8 more

Ranked

1^st among 91 active competitors

Employee Count

64 as on Jul 31, 2026

Similar Companies

Cayman Chem & 100 more

View Genoskin's full profile

Genoskin has raised a total funding of $5.4M over 5 rounds. Its first funding round was on Jun 01, 2018. Its latest funding round was a Series A round on Sep 16, 2025 for $*****. 2 investors participated in its latest round. Genoskin has 9 institutional investors.

Here is the list of recent funding rounds of Genoskin:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Sep 16, 2025	9940123	Series A	3526813	8054888	8784805	5259150
Sep 16, 2025	2283546	Conventional Debt	2602075	7762756	4572468	Bpifrance & 3 more
Aug 29, 2019	1741769	Grant (prize money)	1387699	6466060	2299628	8716831

Access funding benchmarks and valuations. Sign up today!

View details of Genoskin's funding rounds and investors

Genoskin's employee count trend

Genoskin has 64 employees as of Jul 26. Here is Genoskin's employee count trend over the years:

Uncover Genoskin's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Genoskin include Cayman Chem, PhenoVista and Syntax Bio. Here is the list of Top 10 competitors of Genoskin, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Genoskin 2011, Toulouse (France), Series A	In vitro human skin models for preclinical toxicity and efficacy testing	$5.4M	BNP Paribas, Caisse D Epargne & 7 others	54/100
2nd	Cayman Chem 1980, Ann Arbor (United States), Funding Raised	Develops bioreagents and offers preclinical services	-	Tehnopol Startup Incubator, Broadoak Capital Partners ... & 2 others	51/100
3rd	PhenoVista 2014, San Diego (United States), Acquired	High-content imaging and analysis services to accelerate drug discovery	$3M	Fujifilm, Broadoak Capital Partners & 1 others	47/100
4th	Syntax Bio 2018, Chicago (United States), Series A	Preclinical-stage biotech company that develops innovative stem cell-derived therapies by leveraging CRISPR technology	$25M	Sigma Group, DCVC & 13 others	47/100
5th	Lymphogenix 2024, London (United Kingdom), Seed	Developer of therapeutics to enhance lymphatic regeneration for fertility and health	$340K	Keio Innovation Initiative, Glocalink	41/100
6th	Reaction Biology 2001, United States, Late Stage	In vitro enzyme activity assays, secializing in kinase & epigenetic HTS and profiling	-	Cobepa, CYwP Funds & 6 others	40/100
7th	Radiant Research Services 2009, Bengaluru (India), Acquired	Preclinical in vitro testing and development services	-	-	39/100
8th	Discovery Biomed 2007, Birmingham (United Kingdom), Acquired	Contract research organization	-	NIDDK, Greer Capital Advisors & 4 others	39/100
9th	Orient Gene Biotech 2005, China, Unfunded	Manufactrurer and R&D of in vitro diagnostic reagents	-	-	37/100
10th	Bioceros 2003, Utrecht (Netherlands), Acquired	Offers technology platform for the preclinical development of monoclonal antibodies	-	Thuja Capital, BioGeneration Ventures & 1 others	37/100